Genmab says Q3 2026 net sales of DARZALEX total USD 4.24 billion

Genmab reported worldwide net trade sales of DARZALEX of USD 4.24 billion in the third quarter of 2026. U.S. net trade sales reached USD 2.53 billion; rest-of-world sales totaled USD 1.71 billion. Royalty income tied to worldwide DARZALEX net sales reported by Johnson & Johnson under Genmab’s license agreement. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via (Ref. ID: 202610130622PRIMZONEFULLFEED1001277719) on October 13, 2026, and is solely responsible for the information contained therein. (C)